Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study

Journal of Alzheimer's Disease

Volumn 11, Issue 4, 2007, Pages 471-479

  Bakchine, S ^a,b   Loft, H ^c  

^a HÔPITAL MAISON BLANCHE   (France)

^b INSERM   (France)

^c H LUNDBECK A S   (Denmark)

Author keywords

Alzheimer's disease; Memantine; Mild to moderate; NMDA receptor

Indexed keywords

MEMANTINE; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 34447617346     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-11409     Document Type: Article

References (38)

1. A. Burns, M. Rossor, J. Hecker, S. Gauthier, H. Petit, H.-J. Möller and the International Donepezil Study Group, The effects of donepezil in Alzheimer's disease - Results from a Multinational Trial, Dement Geriatr Cogn 10 (1999), 237-244.
2. J. Corey-Bloom, R. Anand and J. Veach, for the ENA 713 B352 study group, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease, Int J Geriatr Psychopharmacol 1 (1998), 55-65.
3. J.L. Cummings and G. Cole, Alzheimer disease, JAMA 287 (2002), 2335-2338.
4. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi and J. Gornbein, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology 44 (1994), 2308-2314.
5. M. Farlow, R. Anand, J. Messina Jr., R. Hartman and J. Veach, A52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, Eur Neurol 44 (2000), 236-241.
6. M.F. Folstein, S.E. Folstein and P.R. McHugh, Mini-Mental state. A practical method for grading the cognitive state of patients for the clinician, J Psychiat Res 12 (1975), 189-198.
7. P.T. Francis, N.R. Sims, A.W. Procter and D.M. Bowen, Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives, J Neurochem 60 (1993), 1589-1604.
8. L. Fratiglioni, D. De Ronchi and H. Aguero-Torres, Worldwide prevalence and incidence of dementia, Drug Aging 15 (1999), 365-375.
9. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, M. Grundman and the Alzheimer's Disease Cooperative Study, An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alz Dis Assoc Dis 11 (1997), S33-S39.
10. N. Hattori, K. Abe, S. Sakoda and T. Sawada, Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease, Neurorepor 13 (2002), 183-186.
11. A.F. Jorm and D. Jolley, The incidence of dementia: a meta-analysis, Neurology 51 (1998), 728-733.
12. J. Kornhuber and M. Weller, Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy, Biol Psychiatry 41 (1997), 135-144.
13. G. Livingston and C. Katona, The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis, Int J Geriatr Psychiatry 19 (2004), 919-925.
14. A. Lobo, L.J. Launer, L. Fratiglioni, K. Andersen, A. Di Carlo, M.M. Breteler, J.R. Copeland, J.F. Dartigues, C. Jagger, J. Martinez-Lage, H. Soininen, A. Hofman and the Neurologic Diseases in the Elderly Research Group, Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts, Neurology 54 (2000), S4-S9.
15. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
16. B.M. McLendon and P.M. Doraiswamy, Defining meaningful change in Alzheimer's disease trials: the donepezil experience, J Geriat Psychiatry Neurol 12 (1999), 39-48.
17. J.M. Orgogozo, A.S. Rigaud, A. Stöffler, H.J. Möbius and F. Forette, Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM300), Stroke 33 (2002), 1834-1939.
18. C.G. Parsons, W. Danysz and G. Quack, Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: A review of preclinical data, Neuropharmacolog 38 (1999), 735-767.
19. J. Pena-Casanova, Alzheimer's Disease Assessment Scale-cognitive in clinical practice, Inl Psychogeriat 9 (1997), S105-S114.
20. E.R. Peskind, S.G. Potkin, N. Pomara, et al., Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial, Am J Geriatr Psychiatry 14 (8) (2006), 704-715.
21. N. Pomara, R. Singh, D. Deptula, J.C. Chou, M.B. Schwartz and P.A. LeWitt, Glutamate and other CSF amino acids in Alzheimer's disease, Am J Psychiatry 49 (1992), 251-254.
22. M.A. Raskind, E.R. Peskind, T. Wessel, W. Yuan and The Galantamine USA-1 Study Group, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension, Neurology 54 (2000), 2261-2268.
23. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, B.A. Norman, C.C. Baranak and the Rofecoxib Protocol 091 Study Group, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology 62 (2004), 66-71.
24. B. Reisberg, L. Schneider, R. Doody, R. Anand, H. Feldman and H. Haraguchi, Clinical global measures of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines, Alz Dis Assoc Dis 11 (1997), S8-S18.
25. B. Reisberg, R. Doody, A. Stoffler, F. Schmitt, S. Ferris and H.J. Mobius, A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease, Arch Neur 63 (2006), 49-54.
26. B. Reisberg, R. Doody, A. Stöffler, F. Schmitt, S. Ferris, H.J. Möbius, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med 348 (2003), 1333-1341.
27. M.A. Rogawski and G.L. Wenk, The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease, CNS Drug Rev 9 (2003), 275-308.
28. S.L. Rogers, M.R. Farlow, R.S. Doody, R. Mohs, L.T. Friedhoff and the Donepezil Study Group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology 50 (1998), 136-145.
29. W.G. Rosen, R.C. Mohs and K.L. Davis, A new rating scale for Alzheimer's Disease, Am J Psychiatry 141 (1984), 1356-1364.
30. W.G. Rosen, R.D. Terry, P.A. Fuld, R. Karzman and A. Peck, Pathologic verification of ischemic score in differentiation of dementias, Ann Neurol 5 (1980), 486-488.
31. M. Rösler, R. Anand, A. Cicin-Sain, S. Gauthier, Y. Agid, P. Dal-Bianco, H.B. Stahelin, R. Hartman and M. Gharabawi on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial, BMJ 318 (1999), 633-638.
32. D.J. Selkoe, The molecular pathology of Alzheimer's disease, Neuron 6 (1991), 487-498.
33. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald and I. Gergel, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA 291 (2004), 317-324.
34. G. Weyer, H. Erzigkeit, S. Kanowski, R. Ihl, and D. Hadler. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial, Int Psychogeriatr 9 (1997), 123-138.
35. G. Wilcock, H.J. Möbius and A. Stöffler, mmm 500group, A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500), Int Clin Psychopharmacol 17 (2002), 297-305.
36. G.K Wilcock, S. Lilienfeld and E. Gaens on behalf of the Galantamine International-1 Study Group, Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial, BMJ 321 (2000), 1445-1449.
37. B. Winblad and N. Poritis, Memantine in severe dementia: results of the M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine), Int J Geriatr Psychiatry 14 (1999), 135-146.
38. B. Winblad, H.J. Mobius and A. Stoffler, Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neural Transm 62 (2002), 217-225.